importance. The smooth operative and postoperative course of the patient documented in this report further supports a role for pulmonary metastasectomy in the treatment of patients with colorectal carcinoma. References 1 Wilking N, Petrelli NJ, Herrera L, Regal AM, Mittelman A. Surgical resection of pulmonary metastases from colorectal adenocarcinoma. Dis Colon Rectum 1985;28: 562-4 2 Hughes ES, McConchie Ii, McDermott FT, Johnson WR, Price AB. Resection of lung metastases in large bowel cancer. Br J Surg 1982;69:410-2 3 Cooper JD, Perelman M, Todd TR, Ginsberg RJ, Patterson GA, Pearson FG. Precision cautery excision of pulmonary lesions. Ann Thorac Surg 1986;41:51-3 4 McCormack PM, Attiyeh FF. Resected pulmonary metastases from colorectal cancer. Dis Colon Rectum 1979;22:553-6 5 Perelman M. Precision techniques for removal of pathological structures from the lungs. Khirurgiia (Mosk) 1983; II:12-6
importance. The smooth operative and postoperative course of the patient documented in this report further supports a role for pulmonary metastasectomy in the treatment of patients with colorectal carcinoma. References Mycosis fungoides is a T-cell lymphoma which may present as eczematous or psoriasiform lesions, generalized plaques, erythroderma or nodular ulcerating lesions. In early stage disease non-specific histological features are frequently seen which are not pathognomonic. Although the tumour usually remains confined to skin for many years, lymph node and visceral involvement may occur as late events and are a frequent postmortem finding1. We report a case of mycosis fungoides who, following successful treatment for extensive cutaneous disease, developed CNS involvement without detectable visceral extension.
Case report A 53-year-old male gave a 4 year history of an itchy rash on his hand. In the year prior to presentation the rash had extended to form erythematous plaques and patches involving the whole integument. The interpretation of several skin biopsies proved difficult showing features of psoriasiform hyperplasia, psoriasiform eczema or erythroderma. However, a confident clinical diagnosis of mycosis fungoides was made. Despite PUVA therapy the disease progressed to form widespread marginated erythematous and infiltrated areas. A further biopsy showed a dermal infiltrate primarily containing cells of the lymphoid series with cytological atypia. No Pautrier abscess formation was seen but the appearances were considered consistent with partially treated mycosis fungoides. Topical nitrogen mustard and UVB therapy were poorly tolerated and the patient was lost to follow-up for 18 months.
He was next reviewed in July 1986 when more extensive plaque and tumour stage disease was present. Further investigations, which included a lymph node biopsy, bone marrow examination, chest X-ray and computed tomography, were all negative. As the disease remained confined to the skin, whole body electron therapy was given with a good response (3000 cGy in 10 fractions over 35 days) and PUVA treatment was also recommenced.
In April 1987 the patient complained of a persistent pyrexia and lethargy. The white cell count was 16.6x iO0fl (polymorphs 87%, lymphocytes 4%, eosinophils 7%) and erythrocyte sedimentation rate 89. No focus of infection was evident and despite screening cultures being sterile, the pyrexia slowly resolved following a course ofbroad spectrum antibiotics. A whole body CT scan was again normal.
The symptoms recurred within 4 weeks of discharge and on this occasion Staphylococcus aureus was isolated from the skin and in one blood culture; intravenous flucloxacillin and gentamicin were given. The patient remained unwell and 9 days later became acutely confused and had a grand mal fit; no neck stiffness or abnormal focal neurological signs were present and the fundi were normal. An enhanced cerebral CT scan showed no abnormality. A lumbar puncture was performed. The cerebrospinal fluid was clear with a pressure of 140 mm ofwater (protein content 0.6 gll, glucose 2.7 mmol/l, red blood cell 60/mm3, white blood cell 42/mm3). Microscopy, culture, auramine stains, indian ink stains and viral serology were all negative. Cytospin preparations, using Romanovsky stain, showed an abnormal immunophenotype consistent with a T-cell lymphoma comprising CD7 (3A1) positive, CD2 (OKT,1) positive, CD3 (OKT3) negative, CD4 (OKT4) negative, CD8 (OKT8) negative and CD19 (Pan-B) negative.
Despite treatment with diazepam, the patient developed status epilepticus. Phenytoin, carbamezepine and chlormethiazole proved ineffective and the fits were finally controlled with thiopentone whose use necessitated a short period of ventilation. Whole brain irradiation (3000 cGy), intrathecal methotrexate and cytosine arabinoside were given. A modest improvement in the patient's condition was seen over several days. However, a further rapid deterioration occurred and death ensued within a week of completing treatment.
Discussion
In the National Cancer Institute review' of mycosis fungoides, most patients presented with non-specific eczematous or 'psoriasiform' eruptions23 and in 50% of cases the diagnosis was only confirmed patho-logically with the development of cutaneous tumours, ulcers or palpable lymph nodes. The presence of Pautrier abscess formation, although a feature of mycosis fungoides, is not a prerequisite for the diagnosis and was absent in 15 of 44 cases reviewed by Rappaport and Thomas4.
Visceral involvement is seen in 50% ofpatients dying with tumour stage diseasel4'5 and when overt is associated with a mean survival of less than 1 year" 5-7. The principal sites of involvement include the lymph nodes (75%), lung (66%), liver (53%) and spleen (60%)1"4 8 although multiple organs are frequently affected'. Despite such widespread dissemination, however, the predominant cause of death in these patients is septicaemia or bacterial pneumonia with Staphylococcus aureus and Pseudomonas aeruginosa being most frequently cultured6'9.
Although visceral involvement is well recognized, clinically detectable CNS disease has only been reported infrequently'0-'5. However, postmortem studies have demonstrated both cerebral and meningeal disease. In one series of 144 patients', 11% had CNS involvement from which the death of 4 patients resulted. Lundberg'5 reported an interesting case of leptomeningeal involvement in whom a 7 month remission was induced with chemotherapy. However, despite very similar treatment in this case only a very tenuous response was seen. 0141-0768/89/ 020116-02/$02.00/0 @1989 The Royal Society of Medicine With more intensive treatment of mycosis fungoides a rise in the incidence of symptomatic CNS involvement may result. This possibility should therefore always be considered if neurological function deteriorates in a patient with advanced cutaneous disease. The new Forum on Clinical Pharmacology and Therapeutics has now met on two occasions. Its inaugural meeting on 24 and 25 March 1988 had the ambitious, yet attainable, title 'Towards Safer Medicines', and discussed the roles of the pharmaceutical industry in design and presentation, and the doctor in the prescribing of medicines. It then went on to examine, in some-detail the pharmaceutical aspects of containers and storage of medicines, particularly in the home, and the importance ofpublic education in their safe handling. Its second meeting, on 12 October 1988, was devoted to the critical scrutiny of 'Restrictive drug listsa worldwide controversy'. The United Kingdom came into this fairly late in the day, and the longer experiences ofAustralia, Sweden, and other countries were reviewed by Dr D de Souza (Australia) and Dr I Angenas (Sweden). The philosophy underlying the British system introduced in April 1985, anda review of its practice was presented by Dr E L Harris (London), who indicated that its primary objective of saving £75 million per year in drug costs had been achieved, and that it had increased the awareness of doctors about their prescribing habits.
Dr L Gerlis (London) conceded that the limited extent ofthe present restricted list had not seriously compromised the income, and so the research expenditure, of most pharmaceutical companies in Britain, but was nevertheless concerned that this scheme was only the thin end of a very thick wedge which could have a serious impact on drug innovation.
A recurring criticism of the scheme from the floor was the lack of information about the influence ofthe restrictive list on drug prescribing and sales. Such information was provided by Mr J S Burton (London), who showed that the scheme had resulted in a reduction of at least 20% in the value of sedative and tranquilizer prescriptions written by general practitioners. Prescriptions for cough medicines, vitamins, antacids and analgesics had also been ignificantly reduced, but there had been a substantial increase in their OTC sales. There was also evidence that a switch to more expensive alternatives (e.g. H2 receptor antagonists) had taken place. These findings were extended and reinforced by presentations on the influence of the restrictive list scheme on the community pharmacist (Mr D Coleman, Norfolk) and the prescribing general practitioner (Dr J Gilleghan, Edinburgh). Undoubtedly there were, and still are, problems between pharmacists and doctors in implementing the system, and the participants seemed to be in general agreement that more consultation between government and the professions should have taken place to avoid these and other logistic problems such as pharmacy drug stocks and the limited availability of a small number of 'white-listed' preparations. In general, however, they concluded that the introduction of the list had probably done little harm and may, indeed, have done some good by accelerating the development of local formularies, both in hospitals and general practice. Although thousands of drugs and formulations are listed in the Brtih -National F.ormu ay, most doctors already restrict their prescribing acrding to their experience and local advice from practice colleagues and hospital consultants. The distillation of such local prescribing 0141-0768/89/ 020117-02/$02.00/0 01989 The Royal Society of Medicine
